Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Kits > PD-L1 > EP-134

PD-L1 [Biotinylated] : B7-1 Inhibitor Screening ELISA Kit

For research use only.

Order Now

EP134-C01High-bind Plate1 plate
EP134-C02Human B7-125 μg
EP134-C03Biotinylated Human PD-L115 μg
EP134-C04Anti-PD-L1 Neutralizing Antibody20 μg
EP134-C05Streptavidin-HRP5 μg
EP134-C06Coating Buffer12 mL
EP134-C0710xWashing Buffer 50 mL
EP134-C08Blocking Buffer50 mL
EP134-C09Substrate Solution12 mL
EP134-C10Stop Solution7 mL
  • Background
    Programmed death molecule 1 and its ligand (PD-1/PD-L1) are a pair of negative immune costimulatory molecules. Under normal circumstances, the combination of PD-L1 on tissue cell surface and PD-1 on lymphocyte surface can inhibit lymphocyte function and induce apoptosis of activated lymphocyte, thus playing an autoimmune tolerance role. However, pD-L1 is also expressed on the surface of various tumor cells. Pd-l1 expressed by tumor cells can bind to PD-1 on the surface of corresponding lymphocytes, inhibit the function of lymphocytes and the release of cytokines, and induce apoptosis of lymphocytes, leading to immune escape of tumor cells. Therefore, blocking the PD-1/PD-L1 pathway can enhance lymphocyte activity to achieve the effect of tumor immunotherapy.
  • Application

    This kit is developed for screening for inhibitors of human PD-L1 binding to human B7-1.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-L1 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human PD-L1 to immobilized human B7-1 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated PD-L1 protein, a human B7-1 protein, an anti-PD-L1 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human B7-1.

    b) Add your molecule of interest to the tests.

    c) Add human PD-L1-Biotin to bind the coated human B7-1.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the half maximal inhibitory concentration (IC50) of your compound to PD-L1: B7-1 binding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to Ds document for the assay protocol.

Serial dilutions of Anti- PD-L1 Neutralizing antibody (Catalog # EP134-C04) (1:1 serial dilution, from 10 μg/mL to 0.039μg/mL) was added into Biotinylated PD-L1: B7-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

  • Clinical and Translational Updates

Comments (0)

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs:7 Details
  • Number of Drugs in Clinical Trials:156 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message